Inoue–Torii A, et al. – The serum and urinary semaphorin3A levels were explored in 72 patients with renal disease and 5 healthy volunteers. A correlation between the urinary semaphorin3A level and the minimal change nephrotic syndrome (MCNS) activity was observed. Data displayed the potential of semaphorin3A as a biomarker for MCNS to clarify the reactivity for therapy. It seemed to be useful in examining other glomerular diseases with proteinuria as well.